Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

NCT06529731 is registered in ClinicalTrials.gov with Sawa Ito, MD as lead sponsor.

NCT NCT06529731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06529731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Lead sponsor
Sawa Ito, MD
Phase
Phase 2
Overall status
Recruiting
Start date
September 23, 2024
Completion date
October 31, 2029
Enrollment
57 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes